Management of chronic osteomyelitis of the femur and tibia: a scoping review

• Published in: EFORT Open Reviews 2021-09, Vol.6 (9), p.704-715
• Main Authors: Arshad, Zaki, Lau, Edward Jun-Shing, Aslam, Aiman, Thahir, Azeem, Krkovic, Matija
• Format: Article
• Language: English
• Subjects: Bone Infection; Clinical trials; Femoral; Femur; General Orthopaedics; Inflammation; Osteomyelitis; Patients; Remission; Remission (Medicine); Research methodology; Tibia; Tibial
• ISSN: 2396-7544; 2058-5241; 2058-5241
• DOI: 10.1302/2058-5241.6.200136

Osteomyelitis refers to an inflammatory process causing bone destruction and necrosis. Managing such a persistent disease is complex, with a number of authors reporting different techniques. This scoping review aims to map and summarize the literature on treatment of chronic femoral and tibial osteomyelitis, in order to improve the reader’s understanding of potential treatments and identify areas of further research. The methodological framework of the Joanna Briggs Institute was followed. A computer-based search was conducted in PubMed, EMBASE, MEDLINE, EMCARE and CINAHL, for articles reporting treatment of chronic tibial/femoral osteomyelitis. Two reviewers independently performed title/abstract and full-text screening according to pre-defined criteria. A total of 1230 articles were identified, with 40 finally included. A range of treatments are reported, with the core principles being removal of infected tissue, dead-space management and antibiotic therapy. The majority (84.5%) of patients presented with stage III or IV disease according to the Cierny–Mader classification, and Staphylococcus aureus was the most commonly isolated organism. The proportion of patients achieving remission with no recurrence during follow-up varies from 67.7–100.0%. The majority of studies report excellent outcomes in terms of infection remission and lack of recurrence. However, identifying specific patient or treatment-related factors which may affect outcomes is currently challenging due to the nature of the included studies and unclear reporting of treatment outcomes. It is now important to address this issue and identify such factors using further high-level research methods such as randomized controlled trials and comparative cohort studies. Cite this article: EFORT Open Rev 2021;6:704-715. DOI: 10.1302/2058-5241.6.200136